Importantly, considering the advantages of measurement of arylesterase over paraoxonase activity, which has lower inter-individual variability and is minimally affected by PON1 polymorphisms, there were studies proposing arylestease and not paraoxonase PON1 as a biomarker for predicting the progression of CKD in T2DM [117,118]. Here, PON1 is linked to chronic kidney disease.